![张连山博士诚邀朋友们出席大会,共同探讨「从引进到出海,中国新药如何做好国际化布局?」这一重要课题!](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
113本新药好书免费送:《新药的故事1-3》《十亿美元分子》《药明康德经典译丛》……中国新药CMC高峰论坛“十三邀”!
![吉利德收到FDA完整回复函(CRL)|成也CMC,败也CMC!](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
CMC问题是影响药品上市的主要原因之一
![吉利德收到FDA完整回复函(CRL)|成也CMC,败也CMC!](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
作为抗病毒龙头药企的吉利德,从“丙肝神药”索磷布韦到“新冠神药”瑞德西韦,缔造了很多传奇。值得我们学习和敬佩!
![吉利德收到FDA完整回复函(CRL)|成也CMC,败也CMC!](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
![吉利德收到FDA完整回复函(CRL)|成也CMC,败也CMC!](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
![吉利德收到FDA完整回复函(CRL)|成也CMC,败也CMC!](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
![吉利德收到FDA完整回复函(CRL)|成也CMC,败也CMC!](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
-
吉利德官网 -
https://endpts.com -
https://www.biospace.com -
Biotech更易收到FDA的“死亡回函”?CMC问题凸显关键性(药渡) -
吉利德17亿美元收购获得的丁肝新药上市申请被FDA拒绝(医药魔方) -
其它公开资料
博腾股份小分子事业部制剂部负责人赵建先生:诚邀您出席2022第三届中国新药CMC高峰论坛!
![吉利德收到FDA完整回复函(CRL)|成也CMC,败也CMC!](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
![吉利德收到FDA完整回复函(CRL)|成也CMC,败也CMC!](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
113本新药好书免费送:《新药的故事1-3》《十亿美元分子》《药明康德经典译丛》……中国新药CMC高峰论坛“十三邀”!
![吉利德收到FDA完整回复函(CRL)|成也CMC,败也CMC!](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
![吉利德收到FDA完整回复函(CRL)|成也CMC,败也CMC!](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
本篇文章来源于微信公众号:药时代
发布者:haitao.zhao,转载请首先联系contact@drugtimes.cn获得授权